Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling
- PMID: 18535174
- PMCID: PMC2438285
- DOI: 10.2353/ajpath.2008.070974
Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling
Abstract
The proinflammatory cytokine interleukin (IL)-1 signals exclusively through the type I IL-1 receptor (IL-1RI). IL-1 expression is markedly induced in the infarcted heart; however, its role in cardiac injury and repair remains controversial. We examined the effects of disrupted IL-1 signaling on infarct healing and cardiac remodeling using IL-1RI(-/-) mice. After reperfused infarction IL-1RI-null mice exhibited decreased infiltration of the infarcted myocardium with neutrophils and macrophages and reduced chemokine and cytokine expression. In the absence of IL-1 signaling, suppressed inflammation was followed by an attenuated fibrotic response. Infarcted IL-1RI(-/-) mice had decreased myofibroblast infiltration and reduced collagen deposition in the infarcted and remodeling myocardium. IL-1RI deficiency protected against the development of adverse remodeling; however, infarct size was comparable between groups suggesting that the beneficial effects of IL-1RI gene disruption were not attributable to decreased cardiomyocyte injury. Reduced chamber dilation in IL-1RI-null animals was associated with decreased collagen deposition and attenuated matrix metalloproteinase (MMP)-2 and MMP-3 expression in the peri-infarct area, suggesting decreased fibrotic remodeling of the noninfarcted heart. IL-1beta stimulated MMP mRNA synthesis in wild-type, but not in IL-1RI-null cardiac fibroblasts. In conclusion, IL-1 signaling is essential for activation of inflammatory and fibrogenic pathways in the healing infarct, playing an important role in the pathogenesis of remodeling after infarction. Thus, interventional therapeutics targeting the IL-1 system may have great benefits in myocardial infarction.
Figures
Similar articles
-
Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling.Circulation. 2007 Nov 6;116(19):2127-38. doi: 10.1161/CIRCULATIONAHA.107.704197. Epub 2007 Oct 22. Circulation. 2007. PMID: 17967775
-
IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium.J Immunol. 2013 Nov 1;191(9):4838-48. doi: 10.4049/jimmunol.1300725. Epub 2013 Sep 27. J Immunol. 2013. PMID: 24078695 Free PMC article.
-
Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodeling.Cardiovasc Res. 2007 May 1;74(2):313-22. doi: 10.1016/j.cardiores.2006.11.028. Epub 2006 Nov 23. Cardiovasc Res. 2007. PMID: 17188669 Free PMC article.
-
Inflammatory mechanisms in myocardial infarction.Curr Drug Targets Inflamm Allergy. 2003 Sep;2(3):242-56. doi: 10.2174/1568010033484098. Curr Drug Targets Inflamm Allergy. 2003. PMID: 14561159 Review.
-
Chemokines in the ischemic myocardium: from inflammation to fibrosis.Inflamm Res. 2004 Nov;53(11):585-95. doi: 10.1007/s00011-004-1298-5. Inflamm Res. 2004. PMID: 15693606 Review.
Cited by
-
Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.Sci Rep. 2024 Feb 9;14(1):3371. doi: 10.1038/s41598-024-53936-x. Sci Rep. 2024. PMID: 38337010 Free PMC article.
-
Engineered heart tissue maturation inhibits cardiomyocyte proliferative response to cryoinjury.J Tissue Eng. 2023 Oct 11;14:20417314231190147. doi: 10.1177/20417314231190147. eCollection 2023 Jan-Dec. J Tissue Eng. 2023. PMID: 37842206 Free PMC article.
-
Intranasal Delivery of Endothelial Cell-Derived Extracellular Vesicles with Supramolecular Gel Attenuates Myocardial Ischemia-Reperfusion Injury.Int J Nanomedicine. 2023 Sep 27;18:5495-5510. doi: 10.2147/IJN.S420301. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37791323 Free PMC article.
-
Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.J Am Heart Assoc. 2023 Oct 3;12(19):e029954. doi: 10.1161/JAHA.123.029954. Epub 2023 Sep 26. J Am Heart Assoc. 2023. PMID: 37750583 Free PMC article.
-
1821-2021: Contributions of physicians and researchers of Greek descent in the advancement of clinical and experimental cardiology and cardiac surgery.Front Cardiovasc Med. 2023 Aug 4;10:1231762. doi: 10.3389/fcvm.2023.1231762. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37600045 Free PMC article. Review.
References
-
- Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2006;13:1877–1893. - PubMed
-
- Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367:356–367. - PubMed
-
- White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51. - PubMed
-
- St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89:68–75. - PubMed
-
- Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543–1553. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
